The value of hyoscine butylbromide in abdominal MR imaging with and without oral magnetic particles.
OBJECTIVE
The purpose of this article was to assess the impact of intravenous (IV) anticholinergic hyoscine butylbromide in abdominal magnetic resonance (MR) imaging with oral magnetic particles (OMP) [ABDOS-CAN, Ferristene (USAN), Nycomed Imaging AS, Oslo, Norway].


METHODS
In 31 patients with abdominal tumors, T1-weighted spin-echo (SE) images (SE 600/ 15; 1.5 T) were obtained without and with IV hyoscine butylbromide (20 mg) before and after administration of 800 ml of OMP. Two blinded readers assessed motion artifacts, bowel-wall visualization, and lesion delineation on the four sets of T1-weighted images. The two-tailed Wilcoxon paired sample test was used for statistical analysis (p < .05).


RESULTS
Hyoscine butylbromide reduced motion artifacts and improved bowel-wall visualization on precontrast and OMP-enhanced images at a statistically significant level (p = 0.0006-0.037). The lowest degree of artifacts was recorded on OMP images with hyoscine butylbromide. OMP with hyoscine butylbromide significantly improved lesion delineation compared to studies without antiperistaltic drug before (p = 0.019) and after OMP administration (p = 0.01).


CONCLUSIONS
The authors conclude that the use of IV hyoscine butylbromide is recommended for OMP-enhanced abdominal MR imaging with T1-weighted SE pulse sequences at 1.5 T.
Laniado
M
M
Department of Diagnostic Radiology, Eberhard-Karls-Universität Tübingen, Germany.
Grönewäller
E
E
Kopp
A F
AF
Kaminsky
S F
SF
Hamm
B
B
Jacobsen
T F
TF
Claussen
C D
CD
D000008:Abdominal Neoplasms / Q000175:diagnosis*; D015746:Abdominal Pain / Q000139:chemically induced; D000284:Administration, Oral; D000328:Adult; D000368:Aged; D016477:Artifacts; D002086:Butylscopolammonium Bromide / Q000008:administration & dosage / Q000009:adverse effects; D003287:Contrast Media / Q000009:adverse effects; D003911:Dextrans; D005260:Female; D052203:Ferrosoferric Oxide; D006801:Humans; D007089:Image Enhancement; D007275:Injections, Intravenous; D007422:Intestines / Q000473:pathology; D007501:Iron / Q000008:administration & dosage / Q000009:adverse effects; D008279:Magnetic Resonance Imaging; D058185:Magnetite Nanoparticles; D008297:Male; D008875:Middle Aged; D018727:Muscarinic Antagonists / Q000008:administration & dosage / Q000009:adverse effects; D010087:Oxides / Q000008:administration & dosage / Q000009:adverse effects; D010528:Peristalsis / Q000187:drug effects; D011446:Prospective Studies; D012449:Safety; D016037:Single-Blind Method; D013535:Suspensions; D014786:Vision Disorders / Q000139:chemically induced; D014839:Vomiting / Q000139:chemically induced
D003287:Contrast Media; D003911:Dextrans; D058185:Magnetite Nanoparticles; D018727:Muscarinic Antagonists; D010087:Oxides; D013535:Suspensions; D002086:Butylscopolammonium Bromide; D007501:Iron; C065507:ferumoxides; D052203:Ferrosoferric Oxide